CAR-T Archives

Interview 28 Sep 2020

From Big Pharma to Startup CEO: Lessons from Kymriah Developer Gaurav Shah

Novartis’ Kymriah, one of the first CAR T-cell therapies to be approved to treat blood cancer, has revolutionized both oncology and gene therapy. Gaurav Shah, now CEO of Rocket Pharmaceuticals, led the team that developed it. Shah began his career as a clinician, but soon moved over into the biotech sector to work at ImClone, […]

September 28, 2020 - 9 minutesmins - By Helen Albert

News and Trends 14 Sep 2020

T-Cell Therapy Firm Wins Massive €93M Series A to Treat Solid Tumors

The Dutch startup Neogene Therapeutics has become the second T-cell therapy developer to raise a spectacularly large Series A round in Europe this year. The Series A round was co-led by the VC firms EcoR1 Capital, Syncona, and Jeito Capital. Neogene Therapeutics will use part of the €93M proceeds to advance its T-cell therapy immuno-oncology […]

September 14, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 11 Aug 2020

How European Startups Have Advanced Cancer T-Cell Therapy in 2020

With the help of a huge €66M Series A round last week, the German startup T-knife is developing cancer T-cell immunotherapies with the help of genetically modified mice. However, this is just one of several cancer T-cell therapy startups making advances this year, with other innovations including off-the-shelf treatments and a potential universal cancer therapy. […]

August 11, 2020 - 8 minutesmins - By Kostas Vavitsas

News and Trends 21 Jan 2020

T-Cell Discovery Could Herald Universal Cancer Immunotherapy

An international research team has found a new type of T-cell that could lead to cell immunotherapies able to treat cancers beyond the reach of current CAR T-cell therapies. Market-approved CAR T-cell therapies including Yescarta and Kymriah have revolutionized cancer treatment by modifying immune T-cells to hunt down cancer cells. However, these treatments are only […]

January 21, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 15 Jan 2020

Adaptimmune to Take Off-The-Shelf CAR-T to Phase I with Astellas

The UK biotech Adaptimmune Therapeutics has inked a deal worth up to €806M with Japanese Astellas Pharma to complete phase I trials of candidate off-the-shelf T-cell therapies for cancer including CAR T-cell and TCR therapies. According to the deal, Adaptimmune will collaborate with Universal Cells, a subsidiary of Astellas. The partners will aim to identify […]

January 15, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 6 Jan 2020

BioNTech’s RNA-Boosted CAR T-Cell Therapy Shrinks Tumors in Mice

A CAR T-cell therapy amplified by RNA technology, developed by BioNTech, has shown preclinical potential for tackling solid tumors, which are hard to treat with current CAR T-cell therapies. In a study published in Science, the CAR T-cell and RNA combination therapy suppressed tumors in mice implanted with human ovarian cancer for longer than regular […]

January 6, 2020 - 2 minutesmins - By Jonathan Smith

Best in Biotech 30 Dec 2019

European Biotech’s Top News in 2019

With the year coming to a close, it’s time to review the most important biotech news events that took place in the European biotech industry in 2019. It has been a solid year for the European biotech industry. In 2019, venture capital funding in Europe continued to be high after a very good year in […]

December 30, 2019 - 10 minutesmins - By Jonathan Smith

News and Trends 9 Dec 2019

Autolus Reveals Early Clinical Data of Next-Gen CAR-T Therapy

London-based Autolus has shown its next-generation CAR T-cell therapy does not induce some of the severe side effects that have led to deaths in patients treated with CAR T-cell treatments currently on the market. Since their arrival on the market in 2017, CAR T-cell therapies have provided hope to patients with rare forms of blood […]

December 9, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Nov 2019

Cellectis’ Off-the-Shelf CAR T-Cell Therapy Shows Solid Tumor Potential

An off-the-shelf, gene edited CAR T-cell therapy, developed by the French biotech Cellectis, could be used to tackle solid tumors, which have so far been beyond the reach of other CAR T-cell therapies. The approved CAR T-cell therapies Kymriah and Yescarta contain genetically modified immune T-cells that can fight certain types of blood cancer. However, […]

November 14, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 12 Nov 2019

First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors

The Belgian company Celyad has released the first interim clinical efficacy data for an off-the-shelf CAR T-cell immunotherapy in solid tumors. The interim results come from an ongoing phase I trial in patients with colorectal cancer. Of the 12 patients given Celyad’s CAR T-cell immunotherapy so far, six have seen their tumors shrink. The therapy […]

November 12, 2019 - 2 minutesmins - By Jonathan Smith

lightcast discovery cell therapy cambridge uk

Startup Scout 27 Sep 2019

This Biotech Can Screen CAR T-Cells Using Only Light and Microfluidics

Based in Cambridge, UK, Lightcast Discovery is developing microfluidics technology that automates cell screening experiments by using lasers. Mission: To automate cell screening experiments, such as those used when screening CAR T-cell immunotherapies. This would let companies test therapies in complex cell experiments, such as cell-to-cell interactions, which are difficult with traditional drug-screening tools. Cell […]

September 27, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 12 Aug 2019

Manufacturing Delays Set Back Autolus’ CAR-T Programs by Five Months

The UK biotech Autolus’ shares have slumped as construction delays from a new manufacturing site have pushed back its CAR-T cell immunotherapy programs. Autolus is developing treatments for blood cancer that involve engineering patients’ own immune cells to kill cancer cells, known as autologous CAR-T cell immunotherapies. Earlier this year, Autolus licensed a new manufacturing […]

August 12, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

CAR-T

From Big Pharma to Startup CEO: Lessons from Kymriah Developer Gaurav Shah

T-Cell Therapy Firm Wins Massive €93M Series A to Treat Solid Tumors

How European Startups Have Advanced Cancer T-Cell Therapy in 2020

T-Cell Discovery Could Herald Universal Cancer Immunotherapy

Adaptimmune to Take Off-The-Shelf CAR-T to Phase I with Astellas

BioNTech’s RNA-Boosted CAR T-Cell Therapy Shrinks Tumors in Mice

European Biotech’s Top News in 2019

Autolus Reveals Early Clinical Data of Next-Gen CAR-T Therapy

Cellectis’ Off-the-Shelf CAR T-Cell Therapy Shows Solid Tumor Potential

First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors

This Biotech Can Screen CAR T-Cells Using Only Light and Microfluidics

Manufacturing Delays Set Back Autolus’ CAR-T Programs by Five Months

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!